Verinurad

Generic Name: Verinurad

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₆N_₂O_₂S

CAS Number: 1352792-74-5

Unique Ingredient Identifier: 12WJ62D047

Background: Verinurad has been used in trials studying the basic science and treatment of Gout, Gout and Hyperuricemia, and Gout and Asymptomatic Hyperuricemia.

Clinical Trials

A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Verinurad prolonged release HPMC capsule
Drug: Verinurad/Allopurinol FDC Capsule
Drug: Verinurad prolonged release gelatin Capsule
Drug: Allopurinol Tablet

First Posted Date: 2020-09-16

Last Posted Date: 2023-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 25

Registration Number: NCT04550234

Locations: 🇩🇪
Research Site, Berlin, Germany

Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Verinurad
Drug: Allopurinol
Drug: Cyclosporine
Drug: Rifampicin

First Posted Date: 2020-08-31

Last Posted Date: 2023-03-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT04532918

Locations: 🇩🇪
Research Site, Berlin, Germany

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Phase 2

Completed

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: Placebo for verinurad
Drug: Verinurad
Drug: Placebo for allopurinol
Drug: Allopurinol

First Posted Date: 2020-03-30

Last Posted Date: 2023-06-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 159

Registration Number: NCT04327024

Locations: 🇸🇰
Research Site, Svidnik, Slovakia

A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

Phase 1

Completed

Conditions: Healthy Volunteers (Intended Indication: Chronic Kidney Disease)

Interventions: Drug: Verinurad
Drug: Placebo
Drug: Allopurinol

First Posted Date: 2020-02-05

Last Posted Date: 2022-01-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT04256629

Locations: 🇩🇪
Research Site, Berlin, Germany

A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Verinurad ER8 capsule formulation (fasted)
Drug: Verinurad B-capsule formulation (fasted)
Drug: Verinurad A-capsule formulation (fed)
Drug: Verinurad B-capsule formulation (fed)
Drug: Verinurad A-capsule formulation (fasted)

First Posted Date: 2019-07-18

Last Posted Date: 2021-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 25

Registration Number: NCT04024501

Locations: 🇩🇪
Research Site, Berlin, Germany

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Phase 2

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Verinurad
Drug: Placebo for Verinurad
Drug: Allopurinol
Drug: Placebo for Allopurinol

First Posted Date: 2019-06-19

Last Posted Date: 2023-03-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 861

Registration Number: NCT03990363

Locations: 🇪🇸
Research Site, Valencia, Spain

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

Phase 1

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Verinurad
Drug: Placebo
Drug: Allopurinol

First Posted Date: 2019-02-11

Last Posted Date: 2019-05-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT03836599

Locations: 🇺🇸
Research Site, Glendale, California, United States

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Phase 2

Completed

Conditions: Asymptomatic Hyperuricemia

Interventions: Drug: Verinurad
Drug: Febuxostat
Drug: Dapagliflozin
Other: Dapagliflozin matched placebo

First Posted Date: 2017-10-20

Last Posted Date: 2019-08-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT03316131

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Phase 2

Completed

Conditions: Hyperuricemia
Albuminuria
Type 2 Diabetes

Interventions: Drug: Verinurad 9 mg+Febuxostat 80 mg
Drug: Placebo

First Posted Date: 2017-04-18

Last Posted Date: 2020-01-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT03118739

Locations: 🇺🇸
Research Site, Webster, Texas, United States

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Phase 1

Completed

Conditions: Gout and Asymptomatic Hyperuricemia

Interventions: Drug: RDEA3170
Drug: Febuxostat
Drug: Benzbromarone

First Posted Date: 2014-12-17

Last Posted Date: 2015-06-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 110

Registration Number: NCT02317861

Locations: 🇯🇵
Research Site, Fukuoka-shi, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy